STC314
STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 401513-39-1
- 分子式: C13H17Na7O32S7
- 分子量:1070.64
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
STC314 (Compound mCBS) (20-100 μg/mL; 1 h) potently inhibits histone-mediated cytotoxicity in HMEC-1 cells[1].
STC314 (12.5-400 μg/mL; 15 min-1 h) blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes[1].
STC314 (mCBS) (0.9-500 μg/mL) stabilizes human NETs and does not displace histones from chicken RBC chromatin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human microvascular endothelial cell-1 (HMEC-1)
-
Concentration:0-100 μg/mL
-
Incubation Time:1 h
-
Result:Inhibited histone-mediated HMEC-1 cytotoxicity.
STC314 (100 mg/kg; i.p.; single dose 2 hours post-histone injection) significantly reduces ongoing histone-induced multi-organ damage and cell death in male C57BL/6 mice when administered 2 hours after histone exposure[1].
STC314 (50 mg/kg; i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery) significantly improves skin flap viability in male Wistar rats following ischemia-reperfusion injury[1].
STC314 (50 mg/kg; i.v.; single dose 5 minutes post-histone injection) almost completely prevents histone-induced deep vein thrombosis in male C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5-6 weeks of age, histone-induced sepsis-like syndrome model)[1]
-
Dosage:6.25 mg/kg; 25 mg/kg; 100 mg/kg
-
Administration:i.p.; single dose 10 minutes pre-histone injection
-
Result:Prevented histone-induced thrombocytopenia (maintained circulating platelet counts near control levels).
Prevented histone-induced anemia (maintained circulating red blood cell counts near control levels and reduced splenic hemoglobin accumulation to near control levels).
Reduced circulating alanine aminotransferase, lactate dehydrogenase, and creatinine levels in a dose-dependent manner, with 100 mg/kg providing the greatest reduction.
-
Animal Model:Wistar (male, 8-12 weeks old, 250-350 g, CLP-induced sepsis model)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; four total doses: 5 minutes pre-CLP, 5, 10, 15 hours post-CLP
-
Result:Resulted in 100% survival of rats at 20 hours post-CLP (compared to reduced survival in untreated controls).
Normalized circulating alanine aminotransferase and creatinine levels, preventing CLP-induced liver and kidney damage.
-
Animal Model:Wistar (male, 8-12 weeks old, 250-350 g, skin flap ischemia-reperfusion injury model)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery
-
Result:Significantly increased the viable area of the ischemic skin flap, with consistent improvement observed across treated rats.
-
Animal Model:C57BL/6 (male, 8 weeks of age, histone-induced deep vein thrombosis model)[1]
-
Dosage:50 mg/kg
-
Administration:i.v.; single dose 5 minutes post-histone injection
-
Result:Almost completely inhibited histone-induced DVT, with thrombus weights reduced to near sham-operated control levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 401513-39-1
-
分子量 1070.64
-
分子式 C13H17Na7O32S7
-
SMILES
O=[S](O[C@H]([C@H]1O[S](=O)(O[Na])=O)[C@@H]([C@H](O[C@H]1OC)CO[S](=O)(O[Na])=O)O[C@H](O[C@@H]2CO[S](=O)(O[Na])=O)[C@@H]([C@H]([C@@H]2O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)(O[Na])=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
STC314 関連分類
HY-145996 関連分類
Powered by Bioz